[1] FDA FY 2016 Regulatory Science Report: Long-Acting InjectableFormulations[EB/OL]. (2017-03-28) [2024-05-14]. https://www. fda. gov/industry/generic-drug-user-fee-amendments/fy2016-regulatory-science-report-long-acting-injectable-formulations
[2] MARTINEZ M, RATHBONE M, BURGESS D, et al. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting[J]. J Control Release, 2008, 129(2):79
[3] CHAUDHARY K, PATEL M, MEHTA P. Long-acting injectables: current perspectives and future promise[J]. Crit Rev Ther Drug Carrier Syst, 2019, 36(2): 137
[4] BAUER A, BERBEN P, SUDHRI S, et al. Current state and opportunities with long acting injectables: industry perspectives from the innovation and quality consortium “Long Acting Injectables” working group[J]. Pharm Res, 2023, 40(7):1601
[5] LU Y, KIM S, PARK K. In vitro-in vivo correlation: perspectives model development[J]. Int J Pharm, 2011, 418(1):142
[6] FDA. Dissolution Methods [EB/OL]. (2022-07-28) [2024-05-14]. https://www. accessdata. fda. gov/scripts/cder/dissolution/dsp_SearchResults. cfm
[7] NANAKI S, BARMPALEXIS P, LATROU A, et al. Risperidone controlled release microspheres based on poly (lactic acid)-poly (propylene adipate) novel polymer blends appropriate for long acting injectable formulations[J]. Pharmaceutics, 2018, 10(3): 130
[8] GRILC B, ZDOVC J, PLANINSEK O. Advanced flow cell design for release testing of mucoadhesive buccal films[J]. Acta Pharm, 2020, 70(3): 359
[9] TANG J, SRINIVASAN S, YUAN WM, et al. Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome[J]. Eur J Pharm Biopharm, 2019, 134: 107
[10] LIU YY, MEI ZH, MEI L, et al. Analytical method development and comparability study for AmBisome (R) and generic amphotericin B liposomal products[J]. Eur J Pharm Biopharm, 2020, 157: 241
[11] CHE X, WANG LH, LI QY, et al. Injectable long-term control-released in situ gels of hydrochloric thiothixene for the treatment of schizophrenia: preparation, in vitro and in vivo evaluation[J]. Int J Pharm, 2014, 469(1):23
[12] TANG J, SRINIVASAN S, YUAN W, et al. Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome[J]. Eur J Pharm Biopharm, 2019(134): 107
[13] KI MH, LIM JL, KO JY, et al. A new injectable liquid crystal system for one month delivery of leuprolide [J]. J Control Release, 2014, 185: 62
[14] DELPLACE CR, BOULLAY OT, SIEPMANN F, et al. PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine[J]. Int J Pharm, 2013, 443(1-2): 68
[15] SHEN J, BURGESS DJ. Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings[J]. Int J Pharm, 2012, 422(1-2): 341
[16] STERNER B, HARMS M, WEIGANDT M, et al. Crystal suspensions of poorly soluble peptides for intra-articular application: a novel approach for biorelevant assessment of their in vitro release[J]. Int J Pharm, 2014, 461(1-2): 46
[17] THINGG M, LARSEN C, ØSTER J, et al. In vitro release from oil injectables for intra-articular administration: importance of interfacial area, diffusivity and partitioning[J]. Eur J Pharm Sci, 2012, 45(3):351
[18] GERNER P, WANG CF, LEE BS, et al. The relationship between functional sciatic nerve block duration and the rate of release of lidocaine from a controlled release matrix[J]. Anesth Analg, 2010, 111(1): 221
[19] ANDHARIYAA JV, SHEN J, CHOI S, et al. Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres[J]. J Control Release, 2017 (255):27
[20] 黄潘雯, 陈菥, 张永太, 等. 往复桶法测定麝香缓释微片的体外释放度[J]. 药物分析杂志, 2024, 44(6):1074
HUANG PW, CHEN X, ZHANG YT, et al. Determination of in vitro release of musk sustained-release mini-tablets by reciprocating cylinder method[J]. Chin J Pharm Anal, 2024, 44(6):1074
[21] GARNER J, SKIDMORE S, PARK H, et al. Beyond Q1/Q2: the impact of manufacturing conditions and test methods on drug release from PLGA-based microparticle depot formulations[J]. J Pharm Sci, 2018, 107(1):353
[22] WANG RF, BAO QY, CLARK AG, et al. Characterization and in vitro release of minocycline hydrochloride microspheres prepared via coacervation[J]. Int J Pharm, 2022, 628:1
[23] NAHATA T, SAINI TR. Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine[J]. J Microencapsul, 2008, 25: 426
[24] WANG SH, ZHANG LC, LIN F, et al. Controlled release of levonorgestrel from biodegradable poly (D, L-lactide-co-glycolide) microspheres: in vitro and in vivo studies[J]. Int J Pharm, 2005, 301: 217
[25] AHMED TA, IBRAHIM HM, SAMY AM, et al. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability[J]. AAPS PharmSciTech, 2014, 15:772
[26] QI F, WU J, YANG TY, et al. Mechanism studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification[J]. Acta Biomater, 2014, 10(10):4247
[27] JU C, SUN J, ZI P, et al. Thermosensitive micelles–hydrogel hybrid system based on poloxamer 407 for localized delivery of paclitaxel. [J]. J Pharm Sci, 2013, 102(8):2707
[28] RAJAGOPAL K, WOOD J, TRAN B, et al. Trehalose limits BSA aggregation in spray-dried formulations at high temperatures: implications in preparing polymer implants for long-term protein delivery[J]. J Pharm Sci, 2013, 102(8):2655
[29] BEGE N, RENETTE T, ENDRES T, et al. In situforming nimodipine depot system based on microparticles for the treatment of posthemorrhagic cerebral vasospasm[J]. Eur J Pharm Biopharm, 2013, 84(1):99
[30] WANG D, ZAHAO JL, LIU XM, et al. Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation[J]. Eur J Pharm Sci, 2014, 60: 40
[31] DELPLACE CR, BOULLAY OT, SAIEPMANN FS, et al. PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine[J]. Int J Pharm, 2013, 443(1-2):68
[32] PARENT M, BOUDIER A, DUPUIS F, et al. Are in situ formulations the keys for the therapeutic future of S-nitrosothiols[J]. Eur J Pharm Biopharm, 2013, 85:640
[33] GHALANBOR Z, KORBER M, BODMEIER R. Interdependency of protein-release completeness and polymer degradation in PLGA-based implants[J]. Eur J Pharm Biopharm, 2013, 85(3):624
[34] USKOKOVIC V, DESAI TA. In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis[J]. J Pharm Sci, 2014, 103(2): 567
[35] AMANN L, GANDAL MJ, LIN R, et al. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia[J]. Pharm Res, 2010, 27(8):1730
[36] TOMAR L, TYAGI C, KUMAR M, et al. In vivo evaluation of a conjugated poly (lactideethylene glycol) nanoparticle depot formulation for prolonged insulin delivery in the diabetic rabbit model. [J]. Int Nanomed, 2012, 8:505
[37] SRIVASTAVA S, SINHA VR. Stavudine loaded biodegradable polymeric microspheres as a depot system for parenteral delivery[J]. Int J Pharm Sci Drug Res, 2013, 5: 1
[38] 刘元芬, 王亚晶, 周咏梅, 等. 纳米给药系统中药物体外释放度测定方法及体内外相关性评价研究进展[J]. 中国药房, 2019, 30(4): 548
LIU YF, WANG YJ, ZHOU YM, et al. Research progress of in vitro drug release determination methods and in vivo and in vitro correlation evaluation in nano drug delivery systems[J]. China Pharm, 2019, 30(4):548
[39] 赵笛, 李菁菁, 张凯, 等. 吸入用瑞德西韦脂质体的制备及其体外评价[J]. 中国药科大学学报, 2021, 52 (5):547
ZHAO D, LI JJ, ZHANG K, et al. Preparation and in vitro characterization of remdesivir-loaded liposomes for inhalation[J]. J China Pharm Univ, 2021, 52(5):547
[40] 林雯, 廖翔茹, 史琼枝, 等. T7/A7R肽修饰的替莫唑胺脂质体制备与表征[J]. 中国药师, 2021, 24 (11):1978
LIN W, LIAO XR, SHI QZ, et al. Preparation and characterization of temozolomide liposomes modified with T7/A7R peptides[J]. China Pharm, 2021, 24(11): 1978
[41] 王懿睿, 杜光. 伊曲康唑自微乳化释药系统体外释放的评价方法[J]. 中国医院药学杂志, 2008, 28(11):877
WANG YR, DU G. Study on evaluation in vitro of release of itraconazole self-microemulsifying drug delivery system[J]. Chin J Hosp Pharm, 2008, 28(11):877
[42] 刘丹, 李淑斌, 鲍洁, 等. 注射用紫杉醇脂质纳米粒的制备、体外释放及体内药动学研究[J]. 中国药学杂志, 2009, 44(17):1320
LIU D, LI SB, BAO J, et al. Preparation, in vitro release and pharmacokinetics of paclitaxel lipid nanoparticles for intravenous injection[J]. Chin Pharm J, 2009, 44(17):1320
[43] 宋波, 黄莺, 郭盈杉. 脂质体体外释放行为评价方法研究进展[J]. 医药导报, 2023, 42(3):384
SONG B, HUANG Y, GUO YS, et al. Research progress of evaluation methods of liposomes release behavior in vitro[J]. Her Med, 2023, 42(3):384
[44] MANNA S, WU Y, WANG Y, et al. Probing the mechanism of bupivacaine drug release from multivesicular liposomes[J]. J Controlled Release, 2019, 294: 279
[45] 张辛宁, 刘杨佳, 吴悦, 等. 紫杉醇衍生物(TAH) 脂质体的处方工艺优化及初步质量评价研究[J]. 中国药剂学杂志, 2021, 19(4): 110
ZHANG XN, LIU YJ, WU Y, et al. Optimization of the formulation technology and preliminary quality evaluation of paclitaxel derivative (TAH) liposomes[J]. Chin J Pharm, 2021, 19(4):110
[46] MONA M, MOTTALEB A, LAMPRECHT A. Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatusI[J]. Drug Dev Ind Pharm, 2011, 37(2): 178
[47] YUAN WM, KUAI R, DAI ZP, et al. Development of a flow-through usp-4 apparatus drug release assay to evaluate doxorubicin liposomes[J]. AAPS J, 2017, 19(1): 150
[48] RUDD ND, HELMY R, DORMER PG, et al. Probing in vitro release kinetics of long-acting injectable nano suspensions via flow-NMR spectroscopy[J]. Mol Pharm, 2020, 17(2):530
[49] GUPTA PK, PANCHOLI SS, DAS P. In vitro drug release testing method for nepafenac ophthalmic suspension[J]. J Pharm Sci, 2024, 113(4):1061
[50] HERRERA LC, DEFAIN MV, HERMIDA LG. In vitro release testing of PLGA microspheres with Franz diffusion cells[J]. Dissol Technol, 2012, 19(2):6
[51] 石玲玲, 陈轶嘉, 朱云龙. 奥泽沙星皮肤外用制剂体外释放的对比研究[J]. 药物分析杂志, 2023, 43(11):1989
SHI LL, CHEN YJ, ZHU YL. Study on in vitro release test conditions of the topical product of ozenoxacin[J]. Chin J Pharm Anal, 2023, 43(11):1989
[52] GRAVES RA, FREEMAN T, MANDAL TK. In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: a technical note[J]. AAPS PharmSciTech, 2007, 8 (3):1
[53] SODERBERG L, DYHRE H, ROTH B, et al. The “inverted cup”-A novel in vitro release techniquefor drugs in lipid formulations[J]. J Controlled Release, 2006, 113(1):80
[54] SODERBERG L, DYHRE H, ROTH B, et al. Ultralong peripheral nerve block by lidocaine:prilocaine 1:1 mixture in a lipid depot formulation:comparison of in vitro, in vivo, and effect kinetics[J]. Anesthesiology, 2006, 104(1):110
[55] 马骏威, 任连杰. 长效注射剂的质量控制[J]. 中国新药杂志, 2022, 31(9):845
MA JW, REN LJ. Quality control of long-acting injections[J]. Chin J New Drugs, 2022, 31(9):845
